AR089067A1 - Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama - Google Patents
Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mamaInfo
- Publication number
- AR089067A1 AR089067A1 ARP120104537A ARP120104537A AR089067A1 AR 089067 A1 AR089067 A1 AR 089067A1 AR P120104537 A ARP120104537 A AR P120104537A AR P120104537 A ARP120104537 A AR P120104537A AR 089067 A1 AR089067 A1 AR 089067A1
- Authority
- AR
- Argentina
- Prior art keywords
- her2
- positive breast
- breast cancer
- cancer
- expression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente proporciona métodos para mejorar el efecto del tratamiento de un régimen de quimioterapia de un paciente que sufre un cáncer de mama HER2-positivo, en particular cáncer de mama HER2-positivo localmente recurrente o metastásico, mediante la adición de bevacizumab (Avastin®) a un régimen de quimioterapia mediante la determinación del nivel de expresión, en particular el nivel de expresión en plasma sanguíneo, de VEGFA y/o de VEGFR2 respecto a los niveles de control de pacientes diagnosticados con cáncer de mama HER2-positivo, en particular cáncer de mama HER2-positivo localmente recurrente o metastásico. La presente proporciona además métodos para evaluar la sensibilidad o capacidad de respuesta de un paciente al bevacizumab (Avastin®) en combinación con un régimen de quimioterapia, mediante la determinación del nivel de expresión, en particular el nivel de expresión en plasma sanguíneo, de VEGFA y/o de VEGFR2 respecto a los niveles de control en pacientes diagnosticados con cáncer de mama HER2-positivo, en particular cáncer de mama HER2-positivo localmente recurrente o metastásico. Composición farmacéutica, kit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11191922 | 2011-12-05 | ||
| EP12171293 | 2012-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089067A1 true AR089067A1 (es) | 2014-07-30 |
Family
ID=47501094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104537A AR089067A1 (es) | 2011-12-05 | 2012-12-03 | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140341893A1 (es) |
| EP (1) | EP2788769A1 (es) |
| JP (1) | JP2015502543A (es) |
| KR (1) | KR20140094594A (es) |
| CN (1) | CN104067128A (es) |
| AR (1) | AR089067A1 (es) |
| AU (1) | AU2012348600A1 (es) |
| BR (1) | BR112014012623A2 (es) |
| CA (1) | CA2854598A1 (es) |
| IL (1) | IL232656A0 (es) |
| MX (1) | MX2014006500A (es) |
| RU (1) | RU2014125520A (es) |
| SG (1) | SG11201402737SA (es) |
| WO (1) | WO2013083499A1 (es) |
| ZA (1) | ZA201403602B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015082880A1 (en) * | 2013-12-02 | 2015-06-11 | Astrazeneca Ab | Methods of selecting treatment regimens |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| CA2968352A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
| US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| AU2017238054B2 (en) | 2016-03-21 | 2023-10-19 | Dana-Farber Cancer Institute, Inc. | T-cell exhaustion state-specific gene expression regulators and uses thereof |
| CN109477843A (zh) * | 2016-07-15 | 2019-03-15 | 豪夫迈·罗氏有限公司 | 用于检测总vegf-a的水平的方法和手段 |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| WO2021076852A1 (en) * | 2019-10-17 | 2021-04-22 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933294A (en) | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| DE68926248T2 (de) | 1989-09-29 | 1996-12-19 | Oncogene Science Inc | p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| DE19806989A1 (de) | 1998-02-19 | 1999-08-26 | Roche Diagnostics Gmbh | Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| DE102004029909A1 (de) | 2004-06-21 | 2006-01-19 | Roche Diagnostics Gmbh | Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern |
| KR101136763B1 (ko) * | 2006-08-21 | 2012-04-24 | 에프. 호프만-라 로슈 아게 | 항-ｖｅｇｆ 항체를 이용한 종양 치료 방법 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US20120190565A1 (en) * | 2009-02-20 | 2012-07-26 | Pangea Biosciences, Inc. | Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm |
| US8427093B2 (en) * | 2010-07-02 | 2013-04-23 | Woodward Hrt, Inc. | Controller for actuation system employing Kalman estimator incorporating effect of system structural stiffness |
| AU2011281702A1 (en) * | 2010-07-19 | 2013-01-31 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| SG187013A1 (en) * | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
-
2012
- 2012-12-03 JP JP2014545192A patent/JP2015502543A/ja active Pending
- 2012-12-03 WO PCT/EP2012/074184 patent/WO2013083499A1/en active Application Filing
- 2012-12-03 BR BR112014012623A patent/BR112014012623A2/pt unknown
- 2012-12-03 CA CA2854598A patent/CA2854598A1/en not_active Abandoned
- 2012-12-03 AR ARP120104537A patent/AR089067A1/es unknown
- 2012-12-03 MX MX2014006500A patent/MX2014006500A/es unknown
- 2012-12-03 RU RU2014125520A patent/RU2014125520A/ru not_active Application Discontinuation
- 2012-12-03 AU AU2012348600A patent/AU2012348600A1/en not_active Abandoned
- 2012-12-03 CN CN201280067538.3A patent/CN104067128A/zh active Pending
- 2012-12-03 KR KR1020147015077A patent/KR20140094594A/ko not_active Application Discontinuation
- 2012-12-03 SG SG11201402737SA patent/SG11201402737SA/en unknown
- 2012-12-03 EP EP12809640.1A patent/EP2788769A1/en not_active Withdrawn
-
2014
- 2014-05-15 IL IL232656A patent/IL232656A0/en unknown
- 2014-05-16 ZA ZA2014/03602A patent/ZA201403602B/en unknown
- 2014-05-28 US US14/289,524 patent/US20140341893A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140094594A (ko) | 2014-07-30 |
| CA2854598A1 (en) | 2013-06-13 |
| JP2015502543A (ja) | 2015-01-22 |
| AU2012348600A1 (en) | 2014-05-22 |
| ZA201403602B (en) | 2015-04-29 |
| BR112014012623A2 (pt) | 2017-06-13 |
| RU2014125520A (ru) | 2016-02-10 |
| SG11201402737SA (en) | 2014-06-27 |
| IL232656A0 (en) | 2014-06-30 |
| NZ624444A (en) | 2016-07-29 |
| WO2013083499A1 (en) | 2013-06-13 |
| US20140341893A1 (en) | 2014-11-20 |
| CN104067128A (zh) | 2014-09-24 |
| MX2014006500A (es) | 2014-08-21 |
| EP2788769A1 (en) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089067A1 (es) | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama | |
| MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
| MX339427B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico. | |
| MX2012007940A (es) | Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab. | |
| MY188938A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| BR112013004673A2 (pt) | biomarcadores e métodos de tratamento. | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| TN2013000464A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
| BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| WO2011094759A3 (en) | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies | |
| BR112014025189A2 (pt) | prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica | |
| BR112014018964A8 (pt) | Anticorpo anti-vegf e uso de um anticorpo anti-vegf | |
| WO2012109632A3 (en) | Crown-like structures as a biomarker for cancer risk and cancer prognosis | |
| ES2570631T3 (es) | Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal | |
| MX2016002529A (es) | Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica. | |
| PH12015500388A1 (en) | Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells | |
| AU2012371260A8 (en) | Predicitive biomarker for cancer treatment with ADCC enhanced antibodies | |
| BR112015027249A2 (pt) | método de diagnóstico de câncer | |
| GB201114909D0 (en) | Biomarkers for lysosomal storage disorders | |
| WO2012138691A3 (en) | Diagnosis and treatment of taxane-resistant cancers | |
| MX2014014821A (es) | Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama. | |
| WO2015036643A3 (es) | Marcador para predecir metástasis del cáncer de mama |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |